New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
05:55 EDTADUS, ADUS, ATRS, ATRS, BGMD, BGMD, DSCO, DSCO, EXPR, EXPR, GSOL, GSOL, KOPN, KOPN, PERI, PERI, SNSS, SNSSCompanies reporting Before the Market Open on Wednesday, March 13
Notable companies reporting before the opening bell on Wednesday include Addus Homecare (ADUS), Antares Pharma (ATRS), BG Medicine (BGMD), Discovery Laboratories (DSCO), Express (EXPR), Global Sources (GSOL), Kopin (KOPN), Perion Network (PERI), and Sunesis Pharmaceuticals (SNSS).
News For ADUS;ATRS;BGMD;DSCO;EXPR;GSOL;KOPN;PERI;SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
10:12 EDTEXPRGap rises after Q4 earnings top forecast, capital return plans announced
Subscribe for More Information
February 25, 2015
07:12 EDTATRSAntares Pharma announces QuickShot testosterone study met primary endpoint
Antares Pharma announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the company’s ongoing, multi-center, phase 3 clinical study evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot auto injector in testosterone deficient adult males. In the study, 150 adult males with hypogonadism low testosterone and testosterone blood levels less than 300 ng/dL received a starting dose of 75 mg of subcutaneously administered testosterone enanthate once weekly for six weeks. Blinded adjustments to dose were made when necessary at week seven based upon the week six pre-dose blood level, and full pharmacokinetic profiles were obtained during the 12th week of treatment. One hundred fifty patients have received at least one dose of study drug and to date, there have been no reported deaths and one serious adverse event of hospitalization for worsening depression. This patient received a single dose of QS T, and the SAE was not considered to be related to study drug. Thus far, there have been no reported adverse events consistent with urticaria. The FDA has recommended that the company create a larger safety database, including approximately 350 subjects exposed to QS T with 200 subjects exposed for six months and 100 subjects exposed for a year. Based on the number of subjects in previous studies and in the current phase 3 study, the company anticipates that it may need approximately 70 additional subjects exposed to QS T for six months.
07:03 EDTPERIPerion Network sees Q1 revenue $50M-$53M, consensus $69.74M
Subscribe for More Information
07:02 EDTPERIPerion Network reports Q4 adjusted EPS 27c, consensus 14c
Reports Q4 revenue $78.68M, consensus $73.28M.
February 18, 2015
10:05 EDTEXPROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
06:51 EDTEXPRExpress upgraded on lower promotional activity at Piper Jaffray
Subscribe for More Information
05:44 EDTEXPRExpress upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use